Utah Medical Products, Inc.

UTMD Healthcare Medical Instruments & Supplies

Utah Medical Products, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $38.5 million, down 5.83% from fiscal 2024. In the quarter to June 2026, revenue fell 14.3%, EPS fell 10.6% and free cash flow fell 55.7%, each against the same quarter a year earlier. Dividend growth for three consecutive years.

74.51 0.41 −0.55%
Market cap
$237.8M
P/E
22.7×
Fwd P/E
28.7×
Dividend yield
1.66%
F-score
6/9
Altman Z
36.25
Beneish M
−2.68
Dividend safety
82/100
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
7 6 6 6

+8 more TTM periods

ROE
8.75% 9.14% 9.54% 9.59%
ROA
8.55% 8.79% 9.21% 9.24%
ROIC
18.60% 20.50% 21.26% 21.87%
Return on Tangible Assets
9.69% 10.18% 10.74% 11.23%
Average Days of Receivables
36.04 35.36 33.37 35.19
Free Cash Flow per Share
3.60 4.09 4.42 4.33
Free Cash Flow
11.45 13.02 14.32 13.88
Capital Expenditures
(0.40) (0.32) (0.37) (0.27)
Other line items
Cash ROIC
5.46% 6.27% 6.99% 6.85%
Accounts Receivable Turnover
10.03 9.90 10.12 10.38
Accounts Payable Turnover
18.85 14.98 20.56 18.76
Inventory Turnover
1.76 1.82 1.97 1.92
Average Days of Payables
21.04 27.61 20.13 16.91
Days of Inventory on Hand
216.19 201.66 175.33 178.78
Tax Rate
(0.19) (0.19) (0.20) (0.20)
Research and Development Expense of Revenue
1.90% 1.78% 1.73% 1.49%
Selling, General and Administrative Expense of Revenue
27.57% 27.34% 25.78% 24.83%
Share Based Compensation of Revenue
1.10% 1.10% 0.97% 0.86%
Operating CF/Net income
1.13 1.23 1.30 1.22
Depreciation/Fixed assets
0.26 0.31 0.30 0.30
Capex/Depreciation
(0.16) (0.11) (0.12) (0.09)
Revenue per Share
11.34 11.78 11.89 12.05
Operating CF per Share
3.72 4.19 4.53 4.41
Capex per Share
(0.13) (0.10) (0.11) (0.08)
Capex to Sales
0.01 0.01 0.01 0.01

Fold the line items

Columns are period end dates